CHARISMA基因亚组.pdfVIP

CHARISMA Genomics CHARISMA Genomics Deepak L. Bhatt MD, MPH, Katy L. Simonsen PhD, Eileen S. Emison PhD, Keith A. A. Fox MBChB, P. Gabriel Steg MD, Gilles Montalescot MD, PhD, Nihar Bhakta MD, Werner Hacke MD, Marcus D. Flather MD, Koon Hou Mak MD, Patrice Cacoub MD, Mark A. Creager MD, Peter B. Berger MD, Steven R. Steinhubl MD, Gurunathan Murugesan PhD, Kandice Kottke- Marchant MD, PhD, A. Michael Lincoff MD, Eric J. Topol MD, on Behalf of the CHARISMA Executive Committee and Investigators Disclosure for Dr. Bhatt Dr. Bhatt has served as a consultant to: Arena, Astra Zeneca, Bristol-Myers Squibb, Cardax, Cogentus, Daiichi Sankyo, Eli Lilly, Eisai, Glaxo Smith Kline, Johnson Johnson, Medtronic, Millennium, Otsuka, Paringenix, PDL, Philips, Portola, sanofi aventis, Schering Plough, Takeda, The Medicines Company, Vertex. Principal Investigator for several potentially related studies. His institution has received funding from Bristol-Myers Squibb, Eisai, Ethicon, Heartscape, Sanofi Aventis, The Medicines Company. This presentation discusses off-label and/or investigational uses of various drugs and devices. This CHARISMA study was funded by sanofi aventis and Bristol-Myers Squibb. The genetic analyses were done by Bristol-Myers Squibb’s Human Genetics and Statistical Genetics Groups. Variability in Clopidogrel Responsiveness in a Diverse Population of 544 Serebruany VL, Steinhubl SR, Berger PB, et al. JACC 2005; 45:246 –51. Genetic Variations and Clopidogrel Response Genetic Variations and Clopidogrel Response Mega JL, Close SL, Wiviott SD, et al. N Engl J Med. 2009;360:354-362. Genetic Variations and Clopidogrel Response Genetic Variations and Clopidogrel Response Heterozygotes vs Homozygotes Heterozygotes vs Homozygotes • Probability of all-cause death, recurrent myocardial infarction, an